Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have been increasingly used for weight loss purposes. Searching for a weight-loss drug but don't like the idea of an ...
Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...
Stocktwits on MSN
VKTX stock slips overnight: Investors pin hopes on fresh weight-loss data as Pfizer joins Eli Lilly, Novo in GLP-1 war
The drugmaker said both late-stage Vanquish studies are fully enrolled ahead of schedule. ・EO Brian Lian said Viking expects to have four late-stage trials underway by the end of 2026. ・Competition in ...
Hosted on MSN
Lilly’s Zepbound seen beating Pfizer injection
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a market analyst who compared the drug to a rival injection from Pfizer. The comment comes as drugmakers race to meet ...
Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results